You are here

FDA Announces Recall of Valsartan-containing Products

An impurity has been found to be carcinogenic.

An impurity called N-nitrosodimethylamine (NDMA) was found in several of products containing valsartan, which is used to treat heart failure and high blood pressure. But not all products containing valsartan are being recalled. And the FDA said that because valsartan is used to treat serious medical condition, patients should keep on taking the recalled products until they have a replacement.

Based on some laboratory tests, researchers have determined that NDMA could cause cancer. “The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured,” the FDA said in a press release.

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status